Australian court rejects British painkiller firm's appeal

Apr 5, 2017

Australia's highest court has rejected British company Reckitt Benckiser's appeal of a 6 million Australian dollar ($4.5 million) fine for misleading consumers about the effectiveness of a popular painkiller

CANBERRA, Australia — Australia's highest court on Wednesday rejected British company Reckitt Benckiser's appeal of a 6 million Australian dollar ($4.5 million) fine for misleading consumers about the effectiveness of a popular painkiller.

The High Court full-bench refused to hear the appeal after Reckitt Benckiser's lawyers outlined its argument for why the fine imposed by the Federal Court in December was too high.

The Federal Court had upheld an appeal by the Australian Competition and Consumer Commission, the watchdog that launched the court action, against the leniency of a AU$1.7 million fine.

Reckitt Benckiser sold Nurofen painkillers that were marketed to relieve specific ailments, such as back pain and menstrual pain, when all of the products contained an identical amount of the same active ingredient, ibuprofen lysine. The court ordered the company to remove the products from Australian stores.

The specific pain products were nearly double the price of Nurofen's standard ibuprofen painkiller and other general pain relief products sold by competitors. The company sold 5.9 million packets of the specific pain products over four years for AU$45 million.

Rod Sims, chairman of the Australian Competition and Consumer Commission, welcomed the High Court ruling. He told Australian Broadcasting Corp that the same offenses would likely be punished by fines of between AU$40 million and AU$50 million under proposed amendments to consumer law that could be legislated this year.

Reckitt Benckiser said it was disappointed by the High Court decision.

"Nurofen did not intend to mislead consumers and we apologize to those of our consumers who were misled," a company statement said. "We recognize that we could have done more to assist our consumers in navigating the Nurofen specific pain range," it added.

More News

The superchip genius or the big name wildcard? Eight contenders to replace Huang as Nvidia’s CEO
Nov 15, 2026
The superchip genius or the big name wildcard? Eight contenders to replace Huang as Nvidia’s CEO

Nvidia chief Jensen Huang has resigned from the chipmaker he co-founded after reports of extramarital affairs made the spotlight.

ASX set for flat start, Nvidia scandal weighs on Wall Street
Nov 15, 2026
ASX set for flat start, Nvidia scandal weighs on Wall Street

US stocks closed lower as a pullback in big AI-focused companies weighed on the market, capping a turbulent week on Wall Street.

The real pain from rising interest rates is yet to come
Nov 15, 2026
The real pain from rising interest rates is yet to come

The number of borrowers who are behind on their mortgage payments is rising, and it’s likely to climb further as rate hikes bite.

Coalition threat to sink gas reform triggers rare industry backlash
Nov 15, 2026
Coalition threat to sink gas reform triggers rare industry backlash

A broad alliance of business chiefs and unions has mounted a last-minute push for the Coalition to pass Labor’s domestic gas-reservation laws.

A new fast-food giant is coming to Australia. Its unusual ingredients aren’t the only talking point
Nov 15, 2026
A new fast-food giant is coming to Australia. Its unusual ingredients aren’t the only talking point

A new chain will enter Australia’s crowded fast-food chicken market after wowing Anthony Albanese at one of its Manila stores. We put some of its dishes to the test.

Wall Street’s wild Nvidia ride delivers big paydays and even bigger bruises
Nov 15, 2026
Wall Street’s wild Nvidia ride delivers big paydays and even bigger bruises

Investors are doubling down on speculative wagers that have delivered both spectacular gains and crushing losses this year.

Inside Boeing’s mission to rebuild trust in the 737 after years of turbulence
Nov 15, 2026
Inside Boeing’s mission to rebuild trust in the 737 after years of turbulence

In the airline industry, attention to detail is everything. Boeing’s recovery is tied to reforms on its manufacturing floor in Washington.

Commercial childcare is hitting a brick wall. Who will pick up the pieces?
Nov 15, 2026
Commercial childcare is hitting a brick wall. Who will pick up the pieces?

Australia’s largest childcare provider has signalled its intent to surrender to a lowball private equity bid as other for-profit providers collapse in record numbers.

‘I don’t care’: Inside Jensen Huang’s last hours as Nvidia CEO
Nov 14, 2026
‘I don’t care’: Inside Jensen Huang’s last hours as Nvidia CEO

At the end, Jensen Huang looked broken and shattered, his legendary energy depleted.

I worked part-time at David Jones. I know exactly why the business failed
Nov 13, 2026
I worked part-time at David Jones. I know exactly why the business failed

Lift operators, bra fitters and lying sales assistants – I mourn you all.

How Elon Musk drove the Cybertruck and Tesla’s ambitions off a cliff
Nov 13, 2026
How Elon Musk drove the Cybertruck and Tesla’s ambitions off a cliff

Elon Musk’s passion project crashed and burned. Its demise carries a lot of weight,

M.J. Bale axed its retail boss while she was on maternity leave. Now she’s fighting back
Nov 13, 2026
M.J. Bale axed its retail boss while she was on maternity leave. Now she’s fighting back

The Australian menswear retailer made its high-flying retail boss redundant days before her scheduled return from parental leave.